Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. develops and markets orthopaedic medical devices for the surgical treatment of bunions and related midfoot deformities. Its updates center on the Lapiplasty® 3D Bunion Correction procedure and related technologies used by surgeons, ambulatory surgery centers and hospitals.
Recurring news themes for TMCI include quarterly and annual financial results, revenue guidance, surgeon adoption, cash and liquidity updates, product introductions and clinical data. Company announcements also cover additions to the bunion and midfoot technology portfolio, including SuperBite™ Compression Screw System, Lapiplasty® Lightning™ technology, SpeedMTP® and IntelliGuide® PSI, as well as patent portfolio activity and presentations at foot and ankle surgery conferences.
Treace (Nasdaq: TMCI) completed the first surgical case using its new HyperPlate™ XM Dynamic Compression Locking Implant, an extension of the SpeedPlate platform. The titanium system uses FastPitch locking screws for rapid insertion and dynamic compression to stabilize midfoot and hindfoot fusion procedures.
The anatomic, ultra-low-profile implants support multiple joint fusions and Evans calcaneal osteotomies, and are paired with single-use sterile instruments, including the GreatReleaseXM™ Rapid Release Instrument. Full commercialization is anticipated in the third quarter of 2026.
Treace (Nasdaq: TMCI) will present at the Sidoti Small Cap Conference on Thursday, June 18, 2026, starting around 1:45 pm ET.
A live webcast and replay will be available on Treace’s investor relations website, where the company also posts information that may be important to investors.
Treace Medical Concepts (Nasdaq: TMCI) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $47.2M (down 10% YoY). Net loss was $18.0M (−$0.28 per share) and adjusted EBITDA was −$5.5M. Cash and marketable securities totaled $51.9M. The company reaffirmed 2026 revenue guidance of $202M–$212M and expects full‑year adjusted EBITDA loss of $4M–$6M, plus a targeted ~50% reduction in cash usage versus 2025.
Treace Medical Concepts (NasdaqGS: TMCI) will report first quarter 2026 financial results before market open on May 8, 2026. Management will host a conference call at 8:00 AM ET the same day. A live and archived webcast will be available on the company investor relations website.
Investors must register to receive dial-in numbers and a unique PIN to join and ask questions.
Treace Medical Concepts (Nasdaq: TMCI) announced first surgical cases using its new SuperBite™ Compression Screw System, designed for variable thread pitch, headless compression, self-drilling and countersinking for rapid insertion.
Full commercialization is anticipated in Q3 2026. Treace said SuperBite and the SpeedXM midfoot system together increase its addressable market by an estimated $300 million.
Treace Medical Concepts (Nasdaq: TMCI) reported Q4 2025 revenue of $62.5M and full-year 2025 revenue of $212.7M (up 2% year-over-year). Q4 net loss was $9.4M and full-year net loss was $59.0M. Adjusted EBITDA improved to a $3.9M loss for 2025 from $11.0M in 2024.
Cash and marketable securities totaled $48.4M at year-end and the company has an additional $115M credit facility. Full-year 2026 guidance: revenue $200M–$212M, Adjusted EBITDA loss $4M–$6M, and ~50% reduction in cash usage versus 2025.
Treace (NasdaqGS: TMCI) will present new product innovations and interim clinical data at the ACFAS Annual Scientific Conference, Feb 24-26, 2026. Key findings include ALIGN3D 48-month recurrence of 8.4%, early weightbearing averages (8.4, 7.9, 3.7 days) across studies, and full radiographic union at six months in SpeedMTP® patients. Treace previewed new devices—SpeedTMT™ (commercial H2 2026) and Lightning™ system (commercial late 2026)—plus Nanoplasty®, Percuplasty™, and IntelliGuide® PSI to broaden its 3D bunion solutions.
Treace Medical Concepts (NasdaqGS: TMCI) will release fourth-quarter and full-year 2025 financial results before market open on Friday, February 27, 2026.
Management will host a conference call at 8:00 am ET with live and archived webcast access via the company investor relations website. Investors must register to receive dial-in details and a unique PIN.
Treace (Nasdaq: TMCI) reported preliminary, unaudited Q4 2025 revenue of $62.1M–$62.5M (≈9% decline at midpoint vs. Q4 2024) and full‑year 2025 revenue of $212.3M–$212.7M (≈2% increase at midpoint vs. 2024), in line with prior guidance of $211M–$213M. The company added ~202 active surgeons in 2025, ending the year with ~3,337 active surgeons (≈33% of an estimated 10,000 U.S. bunion surgeons). Treace cited mid‑single‑digit case volume growth for 3D bunion technologies, said it will not issue full‑year 2026 guidance now, and plans to provide 2026 financial guidance on its Q4 2025 earnings call scheduled for Feb 26, 2026.
Treace Medical Concepts (Nasdaq: TMCI) announced the first surgical case using its new Lapiplasty® Lightning™ technology, an enhancement of the Lapiplasty® System that adds advanced instrumentation and SpeedPlate® Rapid Compression Fixation to reduce steps, correct in three planes, and streamline workflow.
The company plans a limited market release midyear 2026 followed by full commercialization before year-end 2026. A surgeon on Treace's advisory board reported faster procedures with greater accuracy and no need for provisional fixation.